Nohla Therapeutics, a Seattle, WA-based developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, held the second $11M closing of its Series B financing, bringing the total amount raised in this round to $56m.
New investors participating in the second closing included the University of Tokyo Edge Capital, Schroder Adveq and Premier Partners. They joined the initial Series B investor syndicate of Fidelity Management and Research Company, Celgene Corporation, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners.
This additional funding will support its ongoing clinical development of dilanubicel in allogeneic transplant and acute myeloid leukemia, as well as support the advancement of discovery programs from our platform.
Led by Katie Fanning, President and CEO, Nohla Therapeutics is a developer of universal, off-the shelf cell therapies for patients with cancer and other critical diseases. Its proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs.
The company’s lead product candidate, dilanubicel, is currently under evaluation in two ongoing Phase 2 trials for patients with hematologic malignancies undergoing an allogeneic transplant, and acute myeloid leukemia (AML) patients with chemotherapy-induced myelosuppression following high-dose chemotherapy.
Nohla is also pursuing multiple preclinical and discovery programs focused on immune modulation and induction, genetically-modified stem cells for gene therapy and editing, and CAR progenitor and NK cell therapies.